{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T15:32:17Z","timestamp":1769095937801,"version":"3.49.0"},"reference-count":56,"publisher":"Georg Thieme Verlag KG","issue":"02","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The discovery of aquaporin 4 immunoglobulin G (AQP4-IgG) autoantibody, present in \u223c80% of patients with neuromyelitis optica spectrum disorder (NMOSD), dramatically improved its diagnosis, treatment, and prognosis. While Brazil has a higher prevalence of NMOSD (up to 4.5 per 100,000 people) compared with global averages, disparities in access to testing in Brazil impede early diagnosis and treatment. To tackle these issues, the Americas Health Foundation convened a three-day virtual conference with six Brazilian NMOSD experts. This paper emphasizes the importance of addressing the gaps in physicians' knowledge about NMOSD. Stakeholders, including government agencies, should develop national programs for continuing medical education. The public healthcare system should ensure the availability and accessibility of AQP4-IgG antibody testing. Clinical practice guidelines for NMOSD diagnosis and treatment must be established. Such guidelines will enable healthcare providers to manage patients promptly after the initial attack, reducing relapses and improving quality of life. Finally, addressing the fragmented healthcare system, including bridging the gap between public and private institutions and improving access to telemedicine, will aid individuals in Brazil with NMOSD in receiving early diagnosis and treatment. NMOSD presents unique challenges in Brazil because of its higher prevalence and limited access to crucial AQP4-IgG tests. Overcoming these challenges requires collaboration among experts, healthcare providers, government agencies, and the public healthcare system to improve diagnosis, treatment, and patient outcomes.<\/jats:p>","DOI":"10.1055\/s-0045-1801845","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T23:58:52Z","timestamp":1742428732000},"page":"001-011","source":"Crossref","is-referenced-by-count":1,"title":["A roadmap to increasing access to AQP4-Ig testing for NMOSD: expert recommendations"],"prefix":"10.1055","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-3413","authenticated-orcid":false,"given":"Raquel","family":"Vass\u00e3o-Araujo","sequence":"additional","affiliation":[{"name":"Santa Casa de Belo Horizonte (CAPPEM), Departamento de Neurologia, Belo Horizonte MG, Brazil."},{"name":"Cr\u00f4nicos do Dia a Dia, Inova\u00e7\u00e3o Cient\u00edfica e Pesquisa, Guarulhos SP, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3493-1199","authenticated-orcid":false,"given":"Samira","family":"Ap\u00f3stolos","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2980-2421","authenticated-orcid":false,"given":"Angela Marie","family":"Jansen","sequence":"additional","affiliation":[{"name":"Americas Health Foundation, Washington DC, United States."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-681X","authenticated-orcid":false,"given":"Marco A.","family":"Lana-Peixoto","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Faculdade de Medicina, Centro de Pesquisas CIEM MS, Belo Horizonte MG, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0755-9478","authenticated-orcid":false,"given":"Antonio Pereira","family":"Gomes Neto","sequence":"additional","affiliation":[{"name":"Santa Casa de Belo Horizonte (CAPPEM), Departamento de Neurologia, Belo Horizonte MG, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7234-0897","authenticated-orcid":false,"given":"Mariana","family":"Rico-Restrepo","sequence":"additional","affiliation":[{"name":"Americas Health Foundation, Bogota, Colombia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-6730","authenticated-orcid":false,"given":"Soniza Vieira","family":"Alves-Leon","sequence":"additional","affiliation":[{"name":"Universidade Federal do Estado do Rio de Janeiro, Departamento de eurologia, Rio de Janeiro RJ, Brazil."},{"name":"Universidade Federal do Rio de janeiro, Hospital Universit\u00e1rio Clementino Fraga Filho, Centro Pesquisa e Inova\u00e7\u00e3o, Rio de Janeiro RJ, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7695-6020","authenticated-orcid":false,"given":"Douglas Kazutoshi","family":"Sato","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul, Faculdade de Medicina, Porto Alegre RS, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"D M Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"02","key":"ref2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/1352458516663853","article-title":"The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates","volume":"23","author":"S H Hamid","year":"2017","journal-title":"Mult Scler"},{"issue":"01","key":"ref3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"S Jarius","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"07","key":"ref4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneurol.2010.72.","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"S Jarius","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"01","key":"ref5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-10-8","article-title":"The history of neuromyelitis optica","volume":"10","author":"S Jarius","year":"2013","journal-title":"J Neuroinflammation"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"J Y Hor","year":"2020","journal-title":"Front Neurol"},{"issue":"03","key":"ref7","doi-asserted-by":"publisher","first-page":"2055217317730098","DOI":"10.1016\/j.msard.2021.103083","article-title":"Epidemiology of neuromyelitis optica in Latin America","volume":"3","author":"M P Alvarenga","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"04","key":"ref8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"V A Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"103083","DOI":"10.1016\/j.msard.2021.103083","article-title":"Status of the neuromyelitis optica spectrum disorder in Latin America","volume":"53","author":"V M Rivera","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"102807","DOI":"10.1016\/j.msard.2021.102807","article-title":"Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil","volume":"50","author":"M A Lana-Peixoto","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"104488","DOI":"10.1016\/j.msard.2022.104488","article-title":"Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in S\u00e3o Paulo, Brazil","volume":"70","author":"G D Silva","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"01","key":"ref13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12883-022-02621-5","article-title":"Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil","volume":"22","author":"T G Fukuda","year":"2022","journal-title":"BMC Neurol"},{"issue":"03","key":"ref14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/1352458513495580","article-title":"The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project","volume":"20","author":"R M Papais-Alvarenga","year":"2014","journal-title":"Mult Scler"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/ICU.0000000000000703","article-title":"Update on neuromyelitis optica spectrum disorder","volume":"31","author":"K B Holroyd","year":"2020","journal-title":"Curr Opin Ophthalmol"},{"issue":"03","key":"ref16","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1097\/ICU.0000000000000703","article-title":"Pain, depression, and quality of life in neuromyelitis optica spectrum disorder: a cross-sectional study of 166 AQP4 antibody\u2013seropositive patients","volume":"8","author":"I Ayzenberg","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"04","key":"ref17","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: Patient experience and quality of life","volume":"6","author":"J Beekman","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"05","key":"ref18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"D M Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"05","key":"ref19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1590\/0004-282x20130020","article-title":"Patients with neuromyelitis optica have a more severe disease than patients with relapsingremitting multiple sclerosis, including higher risk of dying of a demyelinating disease","volume":"71","author":"D B Bichuetti","year":"2013","journal-title":"Arq Neuropsiquiatr"},{"issue":"07","key":"ref20","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/acn3.51404","article-title":"Mortality of neuromyelitis optica spectrum disorders in a Chinese population","volume":"8","author":"Q Du","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"05","key":"ref21","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"J Palace","year":"2019","journal-title":"Brain"},{"issue":"10","key":"ref22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"P F Zipfel","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"01","key":"ref23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"E Carnero Contentti","year":"2021","journal-title":"J Neuroinflammation"},{"issue":"01","key":"ref24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica","volume":"24","author":"C F Lucchinetti","year":"2014","journal-title":"Brain Pathol"},{"issue":"04","key":"ref25","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/brain\/awab394","article-title":"Spectrum of sublytic astrocytopathy in neuromyelitis optica","volume":"145","author":"Y Guo","year":"2022","journal-title":"Brain"},{"key":"ref26","first-page":"1033","article-title":"My\u00e9lite subaigu\u00eb compliqu\u00e9e de n\u00e9vrite optique","volume":"8","author":"E Devic","year":"1894","journal-title":"Bull M\u00e9d"},{"issue":"03","key":"ref28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis","volume":"59","author":"B G Weinshenker","year":"2006","journal-title":"Ann Neurol"},{"issue":"03","key":"ref29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/WNO.0000000000000396","article-title":"Finding NMO: the evolving diagnostic criteria of neuromyelitis optica","volume":"36","author":"J L Bennett","year":"2016","journal-title":"J Neuroophthalmol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"102428","DOI":"10.1016\/j.msard.2020.102428","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"45","author":"E Carnero Contentti","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1011579","DOI":"10.3389\/fneur.2022.1011579","article-title":"Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD","volume":"13","author":"G Fadda","year":"2022","journal-title":"Front Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.18553\/jmcp.2022.28.s1.s3","article-title":"Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder","volume":"28","author":"D M Wingerchuk","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"issue":"01","key":"ref33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders","volume":"72","author":"E P Flanagan","year":"2015","journal-title":"JAMA Neurol"},{"issue":"06","key":"ref34","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/bpa.12087","article-title":"Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status","volume":"23","author":"D K Sato","year":"2013","journal-title":"Brain Pathol"},{"issue":"02","key":"ref35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/biomedicines7020042","article-title":"Neuromyelitis optica spectrum disorder and anti-MOG syndromes","volume":"7","author":"M A Lana-Peixoto","year":"2019","journal-title":"Biomedicines"},{"issue":"14","key":"ref36","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Y Jiao","year":"2013","journal-title":"Neurology"},{"issue":"05","key":"ref37","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.vaccine.2023.01.003","article-title":"CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series","volume":"41","author":"N Ebrahimi","year":"2023","journal-title":"Vaccine"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"103206","DOI":"10.1016\/j.msard.2021.103206","article-title":"Longitudinally extensive transverse myelitis with positive aquaporin-4 IgG associated with dengue infection: a case report and systematic review of cases","volume":"55","author":"J Comtois","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"04","key":"ref39","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s13365-021-00962-4","article-title":"Clinical and magnetic resonance imaging patterns of extensive Chikungunya virus-associated myelitis","volume":"27","author":"F C Rueda-Lopes","year":"2021","journal-title":"J Neurovirol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"577994","DOI":"10.1016\/j.jneuroim.2022.577994","article-title":"Aquaporin-4 IgG neuromyelitis optica spectrum disorder onset after Covid-19 vaccination: Systematic review","volume":"373","author":"E Harahsheh","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"13","key":"ref41","doi-asserted-by":"publisher","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"M Watanabe","year":"2019","journal-title":"Neurology"},{"issue":"04","key":"ref42","doi-asserted-by":"publisher","first-page":"2055217317743098","DOI":"10.1177\/2055217317743098","article-title":"Serum neurofilament light chain in NMOSD and related disorders: comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status","volume":"3","author":"M S.","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"12","key":"ref43","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1001\/jamaneurol.2020.2743","article-title":"Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders","volume":"77","author":"A Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"issue":"09","key":"ref44","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"R Marignier","year":"2021","journal-title":"Lancet Neurol"},{"issue":"02","key":"ref45","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"S Huda","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review","volume":"27","author":"S Shahmohammadi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"9451","key":"ref47","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"V A Lennon","year":"2004","journal-title":"Lancet"},{"issue":"01","key":"ref48","doi-asserted-by":"publisher","first-page":"e048942","DOI":"10.1136\/bmjopen-2021-048942","article-title":"Incidence of neuromyelitis optica spectrum disorders in China: a large cohort study using claim data","volume":"12","author":"Y Wu","year":"2022","journal-title":"BMJ Open"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"966428","DOI":"10.3389\/fneur.2022.966428","article-title":"The patient journey with NMOSD: From initial diagnosis to chronic condition","volume":"13","author":"G Delgado-Garcia","year":"2022","journal-title":"Front Neurol"},{"issue":"05","key":"ref50","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"A Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"issue":"06","key":"ref51","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"93","author":"S J Pittock","year":"2023","journal-title":"Ann Neurol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"B AC Cree","year":"2019","journal-title":"Lancet"},{"issue":"04","key":"ref53","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"H Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"01","key":"ref54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1590\/s0004-282x2012000100012","article-title":"Treatment of neuromyelitis optica: an evidence based review","volume":"70","author":"D Sato","year":"2012","journal-title":"Arq Neuropsiquiatr"},{"issue":"22","key":"ref55","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"T Yamamura","year":"2019","journal-title":"N Engl J Med"},{"issue":"07","key":"ref56","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"S J Pittock","year":"2019","journal-title":"N Engl J Med"},{"issue":"04","key":"ref58","doi-asserted-by":"publisher","first-page":"e000829","DOI":"10.1136\/bmjgh-2018-000829","article-title":"The Brazilian health system at crossroads: progress, crisis and resilience","volume":"3","author":"A Massuda","year":"2018","journal-title":"BMJ Glob Health"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"743732","DOI":"10.3389\/fneur.2021.743732","article-title":"Fighting Against Stroke in Latin America: A Joint Effort of Medical Professional Societies and Governments","volume":"12","author":"S CO Martins","year":"2021","journal-title":"Front Neurol"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1801845.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T01:09:51Z","timestamp":1742951391000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1801845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":56,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,2,4]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["s00451801845"],"URL":"https:\/\/doi.org\/10.1055\/s-0045-1801845","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}